Trial Outcomes & Findings for Adolescents and Young Adults (AYAs) With Advanced Cancer (NCT NCT05593016)

NCT ID: NCT05593016

Last Updated: 2025-11-03

Results Overview

The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

75 participants

Primary outcome timeframe

Post-treatment (6-8 weeks following the baseline assessment)

Results posted on

2025-11-03

Participant Flow

Two consented participants were lost to follow-up prior to completing the baseline assessment and were not randomized.

Participant milestones

Participant milestones
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Intervention Development (Patients)
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who provided feedback on the program.
Intervention Development (Caregivers)
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were caregivers who provided feedback on the program.
Intervention Refinement
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who tested the first iteration of the program and provided feedback.
Overall Study
STARTED
24
16
17
13
3
Overall Study
Intervention Development
0
0
17
13
0
Overall Study
Intervention Refinement
0
0
0
0
3
Overall Study
Intervention Implementation
24
16
0
0
0
Overall Study
COMPLETED
22
14
15
11
3
Overall Study
NOT COMPLETED
2
2
2
2
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Intervention Development (Patients)
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who provided feedback on the program.
Intervention Development (Caregivers)
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were caregivers who provided feedback on the program.
Intervention Refinement
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who tested the first iteration of the program and provided feedback.
Overall Study
Death
1
1
1
0
0
Overall Study
Lost to Follow-up
1
1
1
2
0

Baseline Characteristics

Adolescents and Young Adults (AYAs) With Advanced Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=24 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=16 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Intervention Development (Patients)
n=17 Participants
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who provided feedback on the program.
Intervention Development (Caregivers)
n=13 Participants
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were caregivers who provided feedback on the program.
Intervention Refinement
n=3 Participants
Participants in this early stage of the study helped us to develop and refine the program that we subsequently used for the randomized controlled trial. These participants were patients who tested the first iteration of the program and provided feedback.
Total
n=73 Participants
Total of all reporting groups
Age, Continuous
24.42 years
STANDARD_DEVIATION 3.68 • n=15 Participants
23.56 years
STANDARD_DEVIATION 3.93 • n=161 Participants
23.47 years
STANDARD_DEVIATION 4.03 • n=100 Participants
49.38 years
STANDARD_DEVIATION 11.41 • n=3 Participants
23.00 years
STANDARD_DEVIATION 4.36 • n=8 Participants
28.21 years
STANDARD_DEVIATION 11.34 • n=7 Participants
Sex: Female, Male
Female
16 Participants
n=15 Participants
8 Participants
n=161 Participants
4 Participants
n=100 Participants
10 Participants
n=3 Participants
3 Participants
n=8 Participants
41 Participants
n=7 Participants
Sex: Female, Male
Male
8 Participants
n=15 Participants
8 Participants
n=161 Participants
13 Participants
n=100 Participants
3 Participants
n=3 Participants
0 Participants
n=8 Participants
32 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=15 Participants
13 Participants
n=161 Participants
1 Participants
n=100 Participants
0 Participants
n=3 Participants
0 Participants
n=8 Participants
17 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants
n=15 Participants
2 Participants
n=161 Participants
16 Participants
n=100 Participants
12 Participants
n=3 Participants
3 Participants
n=8 Participants
54 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=15 Participants
1 Participants
n=161 Participants
0 Participants
n=100 Participants
1 Participants
n=3 Participants
0 Participants
n=8 Participants
2 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=15 Participants
0 Participants
n=161 Participants
0 Participants
n=100 Participants
0 Participants
n=3 Participants
0 Participants
n=8 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Asian
3 Participants
n=15 Participants
0 Participants
n=161 Participants
0 Participants
n=100 Participants
0 Participants
n=3 Participants
0 Participants
n=8 Participants
3 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=15 Participants
0 Participants
n=161 Participants
0 Participants
n=100 Participants
1 Participants
n=3 Participants
0 Participants
n=8 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=15 Participants
4 Participants
n=161 Participants
4 Participants
n=100 Participants
2 Participants
n=3 Participants
0 Participants
n=8 Participants
14 Participants
n=7 Participants
Race (NIH/OMB)
White
16 Participants
n=15 Participants
11 Participants
n=161 Participants
13 Participants
n=100 Participants
9 Participants
n=3 Participants
3 Participants
n=8 Participants
52 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=15 Participants
0 Participants
n=161 Participants
0 Participants
n=100 Participants
0 Participants
n=3 Participants
0 Participants
n=8 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=15 Participants
1 Participants
n=161 Participants
0 Participants
n=100 Participants
1 Participants
n=3 Participants
0 Participants
n=8 Participants
2 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Post-treatment (6-8 weeks following the baseline assessment)

Population: This measure was only provided to participants who received the SMILE Intervention and analyzed among participants receiving at least one AYA SMILE session (n=20) were included in the analysis.

The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=20 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Treatment Acceptability Questionnaire
6.02 score on a scale
Standard Deviation 0.76

PRIMARY outcome

Timeframe: Post-treatment (6-8 weeks following the baseline assessment)

Population: Outcome only applicable to the SMILE Intervention arm.

Treatment feasibility will be assessed by measuring the session attendance percentage for each participant receiving the intervention.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=24 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Session Attendance Percentage
80.20 percentage of sessions
Standard Deviation 39.69

PRIMARY outcome

Timeframe: 12 months following the start of study enrollment

Population: This measure is for individuals who were eligible for the randomized controlled trial. Only patients who were screened for eligibility to participate in the randomized controlled trial are included in this outcome measure.

Number of participants who enrolled in the randomized controlled trial phase of the study after being found eligible.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=97 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Study Enrollment (Randomized Controlled Trial)
42 Participants

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up, one participant with missing data; Education Control Arm: One participant lost to follow-up, one participant with missing data, and one participant died prior to completion of the A2 assessment.

The Brief Pain Inventory is a 9-item, self-report measure assessing pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). Participants rate their pain on a scale from 0 "no pain" to 10 "pain as bad as you can imagine." Pain severity is calculated as the average of four items assessing participants' worst, least, current, and average (in the last week) pain on a scale from 0 "no pain" to 10 "worst pain."

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=22 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=13 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Pain Severity as Measured by the Brief Pain Inventory (BPI)
Baseline
2.49 score on a scale
Standard Deviation 2.35
2.10 score on a scale
Standard Deviation 1.89
Pain Severity as Measured by the Brief Pain Inventory (BPI)
Post-treatment
2.28 score on a scale
Standard Deviation 1.85
2.25 score on a scale
Standard Deviation 1.88

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up and one participant died prior to completion of the A2 assessment.

The Brief Pain Inventory is a 9-item, self-report measure assessing pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). Pain interference is computed as the average of seven items, which ask about the interference of pain across different life domains (e.g., general activity, mood, relations with other people) in the past week on a scale from 0 "Does not interfere" to 10 "Completely interferes." Higher scores indicate higher levels of pain interference.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Pain Interference as Measured by the Brief Pain Inventory (BPI)
Post-treatment
1.91 score on a scale
Standard Deviation 2.04
2.07 score on a scale
Standard Deviation 2.60
Pain Interference as Measured by the Brief Pain Inventory (BPI)
Baseline
2.53 score on a scale
Standard Deviation 2.30
2.45 score on a scale
Standard Deviation 2.66

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up one participant died prior to completion of the A2 assessment.

Fatigue will be assessed using the PROMIS Computer Adaptive Test for Fatigue. Questions ask participants to rate their fatigue during the past 7 days. The T-score ranges from 0 to 100, where higher T-scores indicate greater fatigue. Scores are converted to standardized t-scores with a mean of 50 and standard deviation of 10. T-scores of 55 to \<60 indicate mild levels of fatigue, ≥60 to \<70 indicates moderate levels of fatigue, and ≥70 indicate severe levels of fatigue.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Fatigue as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Baseline
58.64 T-score
Standard Deviation 9.39
54.23 T-score
Standard Deviation 8.87
Fatigue as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Post-treatment
54.67 T-score
Standard Deviation 8.12
51.24 T-score
Standard Deviation 8.99

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up one participant died prior to completion of the A2 assessment.

Depressive Symptoms will be assessed using the PROMIS Computer Adaptive Test for Depression. Questions ask participants to respond to questions during the past 7 days. Scores are converted to standardized T-scores with a mean of 50 and standard deviation of 10. Higher T-scores indicate higher levels of depression. T-scores of 55 to \<60 indicate mild levels of depression, ≥60 to \<70 indicates moderate levels of depression, and ≥70 indicate severe levels of depression.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Depressive Symptoms as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Baseline
56.15 T-score
Standard Deviation 7.56
52.95 T-score
Standard Deviation 10.28
Depressive Symptoms as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Post-treatment
51.35 T-score
Standard Deviation 8.73
52.06 T-score
Standard Deviation 10.41

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up one participant died prior to completion of the A2 assessment.

The Self-Efficacy for Managing Chronic Disease Scale is a 6-item scale. Participants rate their confidence in keeping pain, fatigue, emotional distress, and other symptoms from interfering with things they want to do on a scale from 1 "not at all confident" to 10 "totally confident." The score for the scale is the mean of the six items, with higher number indicating higher self-efficacy.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Self-Efficacy as Measured by the Managing Chronic Disease Scale
Baseline
6.75 score on a scale
Standard Deviation 1.88
7.00 score on a scale
Standard Deviation 2.19
Self-Efficacy as Measured by the Managing Chronic Disease Scale
Post-treatment
7.89 score on a scale
Standard Deviation 1.65
6.90 score on a scale
Standard Deviation 2.17

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up and two participants with missing data on at least one item of the subscale; Education Control Arm: One participant lost to follow-up and one participant died prior to completion of the A2 assessment.

7-Item: The Acceptance and Action Questionnaire-II assesses acceptance, experiential avoidance and psychological flexibility. Question scale ranges from 1, never true, to 7, always true. The total score ranges from 7 to 49, where a higher score indicates greater psychological inflexibility.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=21 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Acceptance and Action
Baseline
21.19 score on a scale
Standard Deviation 10.25
17.50 score on a scale
Standard Deviation 9.15
Acceptance and Action
Post-treatment
19.19 score on a scale
Standard Deviation 9.91
18.43 score on a scale
Standard Deviation 8.25

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up and one participant died prior to completion of the A2 assessment.

The FACIT assesses the spiritual wellbeing of participants with 12-item questionnaire. Responses for each item are on a scale from 0 = "not at all" to 4 = "very much." Three subscale scores (Meaning, Peace, Faith) are calculated by summing specific items. Each subscale has 4 items, with total scores ranging from 0 to 16, with higher scores indicating greater well-being for each subscale (Meaning, Peace, or Faith). A total score is calculated as the sum of the three subscores, with total scores ranging from 0 to 48. Higher scores represent greater spiritual wellbeing.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Post-treatment: Meaning
12.48 score on a scale
Standard Deviation 2.53
11.0 score on a scale
Standard Deviation 4.54
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Baseline: Peace
8.87 score on a scale
Standard Deviation 3.77
9.29 score on a scale
Standard Deviation 4.08
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Post-treatment: Peace
10.28 score on a scale
Standard Deviation 3.73
8.50 score on a scale
Standard Deviation 4.47
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Baseline: Faith
9.87 score on a scale
Standard Deviation 5.81
8.43 score on a scale
Standard Deviation 5.33
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Post-treatment: Faith
11.35 score on a scale
Standard Deviation 5.07
8.50 score on a scale
Standard Deviation 4.96
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Baseline: Total
30.35 score on a scale
Standard Deviation 10.51
30.21 score on a scale
Standard Deviation 10.22
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Post-treatment: Total
34.10 score on a scale
Standard Deviation 10.39
28.00 score on a scale
Standard Deviation 12.31
Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT)
Baseline: Meaning
11.61 score on a scale
Standard Deviation 3.93
12.5 score on a scale
Standard Deviation 3.03

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: One participant lost to follow-up; Education Control Arm: One participant lost to follow-up and one participant died prior to completion of the A2 assessment.

The PROMIS Computer Adaptive Test for Anxiety will be used to assess anxiety symptoms in the last week. Scores are converted to standardized T-scores with a mean of 50 and standard deviation of 10. Higher T-scores indicate higher levels of anxiety. T-scores of 55 to \<60 indicate mild levels of anxiety, ≥60 to \<70 indicates moderate levels of anxiety, and ≥70 indicate severe levels of anxiety.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=23 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Anxiety Symptoms as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Baseline
58.06 T-score
Standard Deviation 10.44
56.64 T-score
Standard Deviation 10.48
Anxiety Symptoms as Measured by PROMIS (Patient-Reported Outcomes Measurement Information System)
Post-treatment
53.81 T-score
Standard Deviation 9.73
53.91 T-score
Standard Deviation 10.40

PRIMARY outcome

Timeframe: Post-treatment (6-8 weeks following the baseline assessment)

Population: Only participants receiving one intervention session had data analyzed. One of these participants had missing data on this item.

The SSTS-R is a 13-item measure. The first 12-items ask participants to rate their satisfaction with the therapy received (6-items) or the therapist delivering the intervention (6-items) on a five-point scale ranging from 1 "strongly disagree" to 5 "strongly disagree." Each of the subscales (Satisfaction With Therapy and Satisfaction With Therapist) range from 6 to 30, with higher scores indicating greater satisfaction. The 13th item (Global Improvement) asks, "How much did the intervention help with your symptoms?" with 5 answer choices ranging from 1 "made things a lot worse" to 5 "made things a lot better," where higher scores indicate a better outcome.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=19 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Intervention Satisfaction as Measured by the Satisfaction With Therapy and Therapist-Revised (SSTS-R)
Satisfaction with therapist subscale
27.57 score on a scale
Standard Deviation 3.10
Intervention Satisfaction as Measured by the Satisfaction With Therapy and Therapist-Revised (SSTS-R)
How much did this intervention help with symptoms?
4.40 score on a scale
Standard Deviation 0.50
Intervention Satisfaction as Measured by the Satisfaction With Therapy and Therapist-Revised (SSTS-R)
Satisfaction with therapy subscale
26.42 score on a scale
Standard Deviation 2.81

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention arm: Work/education, relationships, personal growth/health, leisure: One participant lost to follow-up and two participants had missing data. SMILE Intervention arm: Obstacles: One participant lost to follow-up and four participants had missing data. Education Control Arm: One participant lost to follow-up, one participant died prior to completion of the A2 assessment, and one participant had missing data.

The Bulls Eye Values Survey assists participants with clarifying their values and will be used to examine participants' personal values, values attainment, and persistence towards values in the face of barriers. Part 1 asks the person to record values for 4 domains (work/education, relationships, personal growth/health, and leisure). Then, participants are asked to think of their values in each domain as "bull's eye" (the middle of the dart board). A 1 is equal to a hit in the bull's eye, which means that they are living completely in keeping with their value for that area of living. An 8 is equal to far from the bull's eye, which means that their life is way off the mark in terms of how they are living their life. Part 2 asks the person to identify obstacles to those values and rate from 1, "doesn't prevent me at all", to 7, "prevents me completely".

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=21 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=13 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Values as Measured by the Bulls Eye Values Survey
Baseline: Work/Education
4.43 score on a scale
Standard Deviation 1.94
4.15 score on a scale
Standard Deviation 1.91
Values as Measured by the Bulls Eye Values Survey
Post-treatment: Work/Education
4.71 score on a scale
Standard Deviation 2.26
3.54 score on a scale
Standard Deviation 1.85
Values as Measured by the Bulls Eye Values Survey
Baseline: Leisure
4.62 score on a scale
Standard Deviation 1.88
3.23 score on a scale
Standard Deviation 2.05
Values as Measured by the Bulls Eye Values Survey
Post-treatment: Leisure
4.48 score on a scale
Standard Deviation 1.89
4.23 score on a scale
Standard Deviation 1.59
Values as Measured by the Bulls Eye Values Survey
Baseline: Relationships
4.43 score on a scale
Standard Deviation 2.29
3.54 score on a scale
Standard Deviation 2.33
Values as Measured by the Bulls Eye Values Survey
Post-treatment: Relationship
4.43 score on a scale
Standard Deviation 1.99
3.62 score on a scale
Standard Deviation 2.60
Values as Measured by the Bulls Eye Values Survey
Baseline: Personal growth/health
4.95 score on a scale
Standard Deviation 2.11
4.46 score on a scale
Standard Deviation 2.47
Values as Measured by the Bulls Eye Values Survey
Post-treatment: Personal growth/health
4.95 score on a scale
Standard Deviation 1.96
4.08 score on a scale
Standard Deviation 1.98
Values as Measured by the Bulls Eye Values Survey
Baseline: Obstacles
4.89 score on a scale
Standard Deviation 1.41
4.31 score on a scale
Standard Deviation 1.80
Values as Measured by the Bulls Eye Values Survey
Post-treatment: Obstacles
4.32 score on a scale
Standard Deviation 1.60
4.54 score on a scale
Standard Deviation 1.51

PRIMARY outcome

Timeframe: Post-treatment (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/ follow-up assessment; post-treatment (6-8 weeks following the baseline assessment) reported

Population: This measure was only provided to participants who received the SMILE Intervention and analyzed among participants receiving at least one AYA SMILE session (n=20) were included in the analysis.

Participants' use of intervention strategies will be assessed using a measure developed specific to components of the proposed intervention. Participants will be asked about how frequently treatment strategies discussed in session have been used outside of session since the previous session or last assessment depending on the timing of the questionnaire. A scale ranging from 0 "not at all" to 4 "6 or more days per week" is used.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=20 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Use of Intervention Strategies
2.1 score on a scale
Standard Deviation 0.97

PRIMARY outcome

Timeframe: Baseline, post-treatment/follow-up (6-8 weeks following the baseline assessment), 4 weeks following the post-treatment/follow-up assessment; baseline and post-treatment (6-8 weeks following the baseline assessment) reported

Population: SMILE Intervention: Progress - 1 participant lost to follow-up and 2 participants with missing data at least one item of the subscale; Obstruction - 1 participant lost to follow-up and 1 participant with missing data on at least one item of the subscale Education Control Arm: Progress - 1 participant lost to follow-up and 1 participant died prior to completion of the A2 assessment; Obstruction - 1 participant lost to follow-up and 1 participant died prior to completion of the A2 assessment.

The Valuing Questionnaire is a 10-item self-report questionnaire with a scale 0 = "not true at all" to 6 "completely true." Two subscale scores are calculated, Progress and Obstruction, which typically have a negative correlation. Higher scores on the Progress subscale represent a closer alignment between one's internal values and one's actions. Higher scores on the Obstruction subscale represent more interference with living consistently with one's values. The range for both subscales is 0 to 30.

Outcome measures

Outcome measures
Measure
Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
n=22 Participants
Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
Education Control Arm
n=14 Participants
The control arm will receive the NCI booklet, "Taking Time: Support for People with Cancer" and otherwise continue their usual care.
Living in Alignment With Values: The Valuing Questionnaire (VQ)
Post-treatment: Obstruction
9.50 score on a scale
Standard Deviation 6.46
11.43 score on a scale
Standard Deviation 6.79
Living in Alignment With Values: The Valuing Questionnaire (VQ)
Baseline: Progress
17.05 score on a scale
Standard Deviation 5.57
20.50 score on a scale
Standard Deviation 6.04
Living in Alignment With Values: The Valuing Questionnaire (VQ)
Post-treatment: Progress
18.43 score on a scale
Standard Deviation 5.58
17.93 score on a scale
Standard Deviation 6.66
Living in Alignment With Values: The Valuing Questionnaire (VQ)
Baseline: Obstruction
13.68 score on a scale
Standard Deviation 5.92
10.07 score on a scale
Standard Deviation 6.71

Adverse Events

Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Education Control Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Intervention Development (Patients)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Intervention Development (Caregivers)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Intervention Refinement

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Caroline Dorfman, PhD

Duke University School of Medicine

Phone: 919-416-3473

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place